Monograph

D11AH01 - Tacrolimus

Propably not porphyrinogenic

Rationale

Substrate for CYP 3A4. Strong clinical inhibitor of CYP 3A4 and 1A. Probably insignificant systemic exposure.

Chemical description

Tacrolimus salve 0.1-0.03 % used in atopic dermatitis. Minimal percutaneous absorbtion, blood concentrations in dermal use <1 ng/mL. Metabolized in the liver by CYP 3A4. One report of uneventful systemic use in one patient with AIP. See: Turton-Weeks et al. Prog Transplant 2001 Sept;11(3):214-216)

IPNet drug reports

Uneventful use reported in 2 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes D11A / D11AH or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands

Protopic · Protopic 0,03%, zalf · Protopic 0,1%, zalf · Tacrolimus · Tacrolimus Accord 0,3 mg/g zalf · Tacrolimus Accord 1 mg/g zalf · Takrozem · Takrozem 1 mg/g zalf

Belgium

Protopic · Protopic 0.03 % pommade · Protopic 0.1 % pommade · Takrozem · Takrozem 0.1 % pommade

United Kingdom

Protopic · Protopic 0.03% ointment · Protopic 0.1% ointment · Tacrolimus · Tacrolimus 0.1% in Carmellose gelatin paste · Tacrolimus 0.1% ointment · Tacrolimus 0.3% in Carmellose gelatin paste

Denmark

Protopic · Tacrolimus · Tacrolimus "2care4" · Tacrolimus "Accord" · Tacrolimus "Orifarm" · Tacrolimus "Paranova" · Tacrolimus Accord · Tacronova · Takrozem

Norway